SS
IMDX

SBI Securities’s Insight Molecular Diagnostics IMDX Stock Holding History

SBI Securities’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09K Hold
185
– – ﹤0.01% 2778
2026
Q1 		$607 Hold
185
– – ﹤0.01% 2815
2025
Q4 		$1.39K Hold
185
– – ﹤0.01% 2520
2025
Q3 		$614 Hold
185
– – ﹤0.01% 2891
2025
Q2 		$559 Hold
185
– – ﹤0.01% 2922
2025
Q1 		$566 Hold
185
– – ﹤0.01% 2818
2024
Q4 		$440 Buy
+185
New +$503 ﹤0.01% 2939

Other funds holding IMDX

FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
PSB
Piscataqua Savings Bank Portsmouth, New Hampshire $148M AUM 32.61% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities's IMDX Position: Q2 2026 in Review

SBI Securities held its Insight Molecular Diagnostics (IMDX) position steady in Q2 2026 at 185 shares worth $1.09K. The position accounts for ﹤0.01% of the portfolio, ranked #2778.

SBI Securities first reported a position in IMDX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.39K in Q4 2025. 6 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • SBI Securities held 185 shares of Insight Molecular Diagnostics worth $1.09K as of Q2 2026.
  • SBI Securities left its Insight Molecular Diagnostics share count unchanged in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2778 holding.
  • SBI Securities first reported a position in Insight Molecular Diagnostics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Insight Molecular Diagnostics position peaked at $1.39K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.